Stockscreener 앱 받기
45.06
1.64%
-0.70
전일 마감가:
$45.76
열려 있는:
$45.85
하루 거래량:
218.70K
Relative Volume:
0.14
시가총액:
$5.77B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
23.97
EPS:
1.88
순현금흐름:
$392.71M
1주 성능:
-16.59%
1개월 성능:
-13.06%
6개월 성능:
-1.16%
1년 성능:
+15.77%
1일 변동 폭
$44.82
$46.12
1주일 범위
$42.01
$49.64
52주 변동 폭
$33.15
$65.53
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| HALO | 45.01 | 5.77B | 947.36M | 392.47M | 392.71M | 1.88 |
| VRTX | 448.41 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.45 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.76 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.50 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.65 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Aurora Investment Counsel Sells 12,753 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Segall Bryant & Hamill LLC Has $20.33 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery - MSN
Breaking Down Halozyme Therapeutics: 10 Analysts Share Their Views - Benzinga
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - MSN
Evotec jumps on report Halozyme expressed takeover interest - MSN
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) - MSN
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal - Seeking Alpha
Halozyme Therapeutics (NASDAQ:HALO) Shares Gap UpHere's Why - MarketBeat
Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now? - Yahoo Finance
Are Medical Stocks Lagging Cencora, Inc. (COR) This Year? - Yahoo Finance
Evotec weakPossible defense battle dampens takeover fantasy - Marketscreener.com
Victory Capital Management Inc. Has $23.29 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme CEO: Evotec Is Poised for Growth - Marketscreener.com
Halozyme outlines plan to acquire Evotec for €2 billion - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Halozyme Bids €2B for Evotec, Eyes $2B Revenue by 2025 in Pharma Services Push | EVO Stock News - StockTitan
Royce & Associates LP Decreases Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme (HALO) Eyes $21 Billion Cash Acquisition of Evotec (EVO) - GuruFocus.com
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - Yahoo Finance
The week in pharma: action, reaction and insight – week to November 15 - The Pharma Letter
Cornercap Investment Counsel Inc. Sells 20,204 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
South Street Advisors LLC Purchases New Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Mizuho Markets Americas LLC Trims Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer - MSN
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - AOL
Halozyme Makes Unsolicited €2B Takeover Bid for Drug R&D Services Firm Evotec - MedCity News
Halozyme Therapeutics (NASDAQ:HALO) Shares Gap DownHere's What Happened - MarketBeat
Halozyme Bid For Evotec Does Not Look High Enough - Citeline News & Insights
Halozyme keeps Neutral rating, price target set on acquisition interest By Investing.com - Investing.com UK
Halozyme offers €11 per share to acquire Evotec for €2bn - World Pharmaceutical Frontiers
Halozyme sets out offer to acquire Evotec - The Pharma Letter
Evotec spikes on buyout proposal from Halozyme - FirstWord Pharma
Halozyme offers $2B for Evotec to expand beyond tech used by J&J - Fierce Biotech
US competitor Halozyme offers two billion euros for Evotec - Marketscreener.com
Halozyme bids for Evotec; BeiGene gets a new name - Yahoo Finance
Evotec surges on Halozyme takeover interest - ShareCast
Market news - Research the market
Germany’s Evotec Gets Takeover Interest From Halozyme - Yahoo Finance
Halozyme (HALO) Aims for Global Innovation through Evotec Purchase - Value the Markets
HALOZYME THERAPEUTICS INC : JP Morgan gives a Neutral rating - Marketscreener.com
Halozyme proposes $2 billion acquisition of Evotec - Investing.com India
Halozyme Therapeutics Bids to Acquire German Competitor Evotec - MarketWatch
Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports - MSN
Halozyme makes 2 billion euro buyout offer for drug developer Evotec - Reuters.com
Halozyme Bids €2B to Acquire Evotec, Offers 109% Premium in Major Biotech Deal | HALO Stock News - StockTitan
HALO Stock Dips 5.77% Amid Biotech Sector Changes - GuruFocus.com
Evotec jumps as Halozyme confirms takeover interest (updated) - Seeking Alpha
Halozyme interested in acquiring Evotec for $2.1B, Bloomberg says - TipRanks
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Future Fund LLC - MarketBeat
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Oct 15 '24 |
Option Exercise |
18.15 |
10,000 |
181,455 |
183,756 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Oct 15 '24 |
Sale |
53.75 |
10,000 |
537,469 |
173,756 |
| LaBarre Michael J. | SVP, CHIEF TECHNICAL OFFICER |
Oct 16 '24 |
Sale |
53.26 |
10,000 |
532,590 |
173,756 |
0.42%
0.16%
자본화:
|
볼륨(24시간):